Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | BRS3 | P32247 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843460 | 0.78 | CYP11B2 (0.41) | ALDH1A1HPGDIDO1CYP3A4CYP2D6 | |
| SCHEMBL843400 | 0.76 | IDO1 (0.33) | ALDH1A1HPGDIDO1CYP3A4CYP2D6 | |
| SCHEMBL843399 | 0.75 | IDO1 (0.34) | ALDH1A1HPGDIDO1CYP3A4CYP2D6 | |
| SCHEMBL842330 | 0.66 | CYP11B2 (0.42) | IDO1CYP11B2 | |
| SCHEMBL2817119 | 0.64 | IDO1 (0.33) | IDO1CYP11B2 | |
| SCHEMBL842521 | 0.64 | CYP11B2 (0.43) | IDO1CYP11B2 | |
| SCHEMBL842704 | 0.61 | CYP11B2 (0.57) | CYP3A4CYP11B2 | |
| SCHEMBL2817782 | 0.59 | CYP11B2 (0.37) | CYP11B2 | |
| SCHEMBL843156 | 0.58 | CYP11B2 (0.44) | IDO1CYP11B2 | |
| SCHEMBL843207 | 0.58 | SMN1; SMN2 (0.42) | ALDH1A1HPGDIDO1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2121652-A1 | 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008076860-A1 | 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093711-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP11B2 | ALDH1A1 142/4885HPGD 202/4885IDO1 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.